OPM Biosciences

OPM Biosciences (奥浦迈) is a cell-culture media company whose industrial capabilities have made it a sought-after partner for biomanufacturing-focused investment funds. In late 2025, it co-launched Shanghai's first bio-manufacturing industry fund with Dalton Venture (道彤投资), a "C+VC" vehicle totaling RMB 1 billion that combines OPM's upstream supply-chain expertise with the firm's early-stage healthcare and synthetic-biology deal experience . OPM and Dalton also jointly convened the "Life Derives All Things" bio-manufacturing industry partners conference in Shanghai that same month . Beyond the fund, OPM sits on the inaugural steering committee of the "Bio-Manufacturing Industry Value Partners" alliance alongside Dalton, Novo Holdings, Meihua Bio, and academic institutions such as East China University of Science and Technology—an effort aimed at closing the "last kilometer" between lab research and production-line application . The company's positioning in the bundle is as a manufacturing-platform player rather than a drug developer, with its strategic value lying in cell-culture media as a bottleneck input for biologics and synthetic-biology production.